Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. Silo focuses on developing traditio... Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. Silo focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The Company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Silo's two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). Silo's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. Mehr anzeigen
Key preclinical milestone for novel, non-opioid extended-release pain therapeutic SARASOTA, FL, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”...
Prototype development and feasibility testing underway for optimized subcutaneous delivery SARASOTA, FL, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the...
Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical study for managing severe conditions The Company is currently developing...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0415 | -4.50939910899 | 0.9203 | 0.9893 | 0.7707 | 310940 | 0.86507682 | CS |
| 4 | -0.0312 | -3.42857142857 | 0.91 | 1.11 | 0.77 | 623813 | 0.97594021 | CS |
| 12 | -0.1712 | -16.3047619048 | 1.05 | 1.35 | 0.77 | 301042 | 1.01582519 | CS |
| 26 | -0.0813 | -8.46786793042 | 0.9601 | 4.5 | 0.77 | 2685638 | 2.59323012 | CS |
| 52 | -0.7012 | -44.3797468354 | 1.58 | 4.5 | 0.77 | 1458842 | 2.53496981 | CS |
| 156 | -5.7212 | -86.6848484848 | 6.6 | 7.26 | 0.77 | 792719 | 2.58960892 | CS |
| 260 | -5.7212 | -86.6848484848 | 6.6 | 7.26 | 0.77 | 792719 | 2.58960892 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
